New Test Predicts Tumors Most Likely to Respond to Radiation, Chemotherapy
Many cancer patients might respond better to treatments with the help of a new prognostic indicator based on a distinctive pattern of gene activity within tumor cells.
University of California San Francisco
Give to UCSFMany cancer patients might respond better to treatments with the help of a new prognostic indicator based on a distinctive pattern of gene activity within tumor cells.
A new study finds that inherited genetic variation plays a role in who is likely to benefit from checkpoint inhibitors, which release the immune system’s brakes so it can attack cancer.
UCSF scientists have discovered a new way to control the immune system’s “natural killer” cells, a finding with implications for novel cell therapies and tissue implants that can evade immune rejection.
Immunotherapies are a promising anticancer arsenal and work by mobilizing the immune system to recognize and destroy cancer cells. Currently, however, only a third of patients respond to
Finding medicines that can kill cancer cells while leaving normal tissue unscathed is a Holy Grail of oncology research.
A new, $9 million grant from the National Cancer Institute to increase ethnic diversity will help the study work toward a goal of enrolling 100,000 or more women overall.
Climate change will bring an acute toll worldwide, with rising temperatures, wildfires and poor air quality, accompanied by higher rates of cancer, especially lung, skin and gastrointestinal cancers.
Researchers found that patients with a pediatric cancer who were protected under the ACA’s dependent coverage provision were more likely to remain on private insurance for longer durations compared to their older peers who turned 19 before the Act.
Risk for melanoma, the most deadly skin cancer, can be estimated long before detection of any suspicious moles, according to a UCSF scientist.
Though cancer immunotherapy has become a promising standard-of-care treatment – and in some cases, perhaps a cure – for a wide variety of different cancers, it doesn’t work for everyone, and researchers have increasingly turned their attention to understanding why.
Researchers have figured out how to assemble genetic profiles of individual lung cancer cells obtained from patients at different times during the course of their treatment.
None of the individual tumor genetic differences that were identified are likely to explain significant differences in health outcomes or to prevent Black Americans from benefiting from a new generation of precision prostate cancer therapies, researchers say, as long as the therapies are applied equitably.
A new model of the causes of breast cancer, created by a team led by researchers at UCSF, Genentech and Stanford University, is designed to capture the complex interrelationships between dozens of primary and secondary breast cancer causes and stimulate further research.
Under a new agreement, Celgene will further invest in the RAN’s state-of-the-art antibody engineering program to expand target discovery from oncology and immunology to include neurology.
The finding could offer additional insights into other immune conditions, including a type of childhood leukemia and the severe inflammation response in some children with COVID-19.